STREAM BIOMEDICAL INC
Perlecan-based therapeutic to enhance blood-brain barrier integrity and neurovascular unit function in brain injury recovery
- Sector
- Biotech
- Headquarters
- College Station, TX
- Latest Form D
- $21.5M, Jan 2022
- Total capital
- $25.3M
- Federal grants
- $3.8M
- 5 awards · 2019–2021
- Rank in peer group#379 of 502
- Private capital raised
- $21.5M
- 1 Form D · last Jan 2022
- 58 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$21.5M
- Federal grantHealth and Human S · Phase II · Selection & Optimization of a Therapeutic Protein for Acute Ischemic Stroke Functional Recovery$701K
- Federal grantHealth and Human S · Phase II · Selection & Optimization of a Therapeutic Protein for Acute Ischemic Stroke Functional Recovery$1.6M
- Federal grantHealth and Human S · Phase I · in vitro and in vivo Assessments of Novel Protein Therapy for Disease Modification in Alzheimer's Mice$393K
- Federal grantHealth and Human S · Phase I · in vitro and in vivo Assessments of Novel Protein Therapy for Disease Modification in Alzheimer's Mice$393K
- Federal grantHealth and Human S · Phase II · Selection & Optimization of a Therapeutic Protein for Acute Ischemic Stroke Functional Recovery$768K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
31months
from STREAM BIOMEDICAL INC’s first federal award to its first private round.
- First federal award · Jun 2019
- Health and Human S · $768K
- First Form D · Jan 2022
- $21.5M · 1st Form D
- Awards before first raise
- 5 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#16 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amanda De La GarzaDirectorNamed in SEC Form D filings
- Chris GarabedianDirectorNamed in SEC Form D filings
- Fred CalloriDirectorNamed in SEC Form D filings
- William SchwietermanExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingUse Of Perlecan And Fragments Thereof To Reduce The Risk Of Death In Stroke PatientsUSPTOApplication 18017669
- PendingUse Of Perlecan And Fragments Thereof To Treat Blood-brain Barrier DisruptionUSPTOApplication PCTUS2023082138
- PendingUse Of Perlecan And Fragments Thereof To Treat Blood-brain Barrier DisruptionUSPTOApplication 63385718
Show all 5 patent records
- Use Of Perlecan And Fragments Thereof To Reduce The Risk Of Death In Stroke PatientsSep 21, 2023 · Application 18017669Pending
- Use Of Perlecan And Fragments Thereof To Treat Blood-brain Barrier DisruptionApplication PCTUS2023082138Pending
- Use Of Perlecan And Fragments Thereof To Treat Blood-brain Barrier DisruptionApplication 63385718Pending
- Use Of Perlecan And Fragments Thereof To Reduce The Risk Of Death In Stroke PatientsApplication PCTUS2021070948Pending
- Use Of Perlecan And Fragments Thereof To Reduce The Risk Of Death In Stroke PatientsApplication 63061308Pending
Recent research by its founders
- Recombinant Human Perlecan Domain V Laminin-like Globulin Domain 3 (rhPDVLG3): A Basement Membrane-derived Matrikine Targeting Neurovascular Injury and Repair20250 cites
- Ethics of Articular Cartilage Surgery20240 cites
- Recombinant Human Perlecan DV and Its LG3 Subdomain Are Neuroprotective and Acutely Functionally Restorative in Severe Experimental Ischemic Stroke20227 cites
Related companies, and why
- CERAMIDE THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- Actinium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- PhaseBio Pharmaceuticals IncSimilar federal contract value in Biotech · null in contracts
- TWOXAR, INC.Similar federal contract value in Biotech · null in contracts
- PRIMROSE BIO, INC.Similar federal contract value in Biotech · null in contracts
- XDEMICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .